Last reviewed · How we verify
NCT07170345: HCC-MVI-CAD
Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
trial testing Computer-Aided Diagnosis System for Preoperative Prediction of MVI in HCC in Hepatocellular Carcinoma (HCC) in 400 participants. Currently enrolling.
1 September 2026
Quick facts
| Lead sponsor | Chinese Academy of Sciences |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 400 |
| Start date | 1 September 2025 |
| Primary completion | 1 September 2026 |
| Estimated completion | 1 September 2027 |
| Sites | 19 locations across China |
Drugs / interventions tested
- Computer-Aided Diagnosis System for Preoperative Prediction of MVI in HCC
Conditions studied
- Hepatocellular Carcinoma (HCC) — all drugs for Hepatocellular Carcinoma (HCC) →
- Microvascular Invasion (MVI) — all drugs for Microvascular Invasion (MVI) →
Sponsor
Chinese Academy of Sciences — full company profile →
Who can join
Adults 18 to 18, any sex, with Hepatocellular Carcinoma (HCC) or Microvascular Invasion (MVI). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Hepatocellular carcinoma (HCC) is a common malignancy in China with a high mortality rate. Its early recurrence and long-term prognosis are closely associated with tumor aggressiveness. Microvascular invasion (MVI), defined as the presence of tumor cells within small branches of the portal or hepatic veins, is a key indicator of malignant biological behavior in HCC. Clinically, MVI is strongly correlated with postoperative early recurrence and serves as an important factor in determining surgical margin extension, adjuvant therapy, and postoperative management strategies. At present, definitive diagnosis of MVI still relies on postoperative pathological examination, and stable, effective preoperative assessment methods are lacking. Although some studies have attempted to predict MVI using preoperative imaging features, their clinical translation remains limited by poor generalizability, weak interpretability, and insufficient cross-center adaptability. This study aims to leverage multiphase preoperative CT imaging, artificial intelligence techniques, and clinical prior knowledge to develop a high-performance, generalizable, and interpretable computer-aided diagnostic system for preoperative prediction of HCC-MVI. An observational, prospective evaluation will be conducted to assess system performance and to facilitate the clinical translation of intelligent diagnostic technologies in real-world practice.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
[Diagnosis and treatment of liver diseases in the era of artificial intelligence].
Ren LY, Chen DB, Chen HS. · · 2025 · PMID 41461549 · DOI 10.3760/cma.j.cn501113-20250910-00376
Verify or expand the search:
- PubMed search for NCT07170345
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hepatocellular Carcinoma (HCC)
Currently open trials in the same condition.
- NCT07070076 — A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Ther · NA · recruiting
- NCT07476651 — Scout Dose of Resin Microspheres · NA · recruiting
- NCT07419841 — A Phase 1 Study of the Safety and Tolerability of CTX-10726 · Phase 1 · recruiting
- NCT07490262 — A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular · Phase 2, PHASE3 · recruiting
- NCT07291076 — A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants Wit · Phase 1, PHASE2 · recruiting
Other Chinese Academy of Sciences trials
Trials by the same sponsor.
- NCT07158372 — Research on Identifying Critical Surgical Anatomy in Cholecystectomy Videos Based on Deep Learning · recruiting
- NCT06989177 — Probiotic Intervention on Body Weight · NA · recruiting
- NCT06989203 — Protein Supplementation Intervention on Body Weight · NA · recruiting
- NCT06035250 — AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy · recruiting
- NCT06002412 — Quality Control of Ultrasound Images During Early Pregnancy Via AI · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07170345 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese Academy of Sciences
- Last refreshed: 12 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07170345.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing